Ultane is a drug owned by Abbvie Inc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 09, 2018. Details of Ultane's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6074668 (Pediatric) | Container for an inhalation anesthetic |
Jul, 2018
(7 years ago) |
Expired
|
| US6074668 | Container for an inhalation anesthetic |
Jan, 2018
(7 years ago) |
Expired
|
|
US6288127 (Pediatric) | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(8 years ago) |
Expired
|
|
US5990176 (Pediatric) | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(8 years ago) |
Expired
|
|
US6444859 (Pediatric) | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(8 years ago) |
Expired
|
| US6288127 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(8 years ago) |
Expired
|
| US5990176 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(8 years ago) |
Expired
|
| US6444859 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Ultane's patents.
Latest Legal Activities on Ultane's Patents
Given below is the list of recent legal activities going on the following patents of Ultane.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation
Critical | 03 Sep, 2002 | US6444859 |
| Recordation of Patent Grant Mailed
Critical | 03 Sep, 2002 | US6444859 |
| Issue Notification Mailed
Critical | 15 Aug, 2002 | US6444859 |
| Receipt into Pubs | 06 Aug, 2002 | US6444859 |
| Application Is Considered Ready for Issue
Critical | 05 Aug, 2002 | US6444859 |
| Receipt into Pubs | 02 Aug, 2002 | US6444859 |
| Response to Amendment under Rule 312
Critical | 30 Jul, 2002 | US6444859 |
| Mail Response to 312 Amendment (PTO-271)
Critical | 30 Jul, 2002 | US6444859 |
| Receipt into Pubs | 01 Jul, 2002 | US6444859 |
| Issue Fee Payment Verified
Critical | 18 Jun, 2002 | US6444859 |
US patents provide insights into the exclusivity only within the United States, but
Ultane is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Ultane's family patents as well as insights into
ongoing legal events
on those patents.
Ultane's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ultane's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 09, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ultane Generic API suppliers:
Sevoflurane is the generic name for the brand Ultane. 5 different companies have already filed for the generic of Ultane, with Baxter Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ultane's generic
How can I launch a generic of Ultane before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Ultane's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Ultane's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Ultane -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100%, 250 mL |
About Ultane
Ultane is a drug owned by Abbvie Inc. Ultane uses Sevoflurane as an active ingredient. Ultane was launched by Abbvie in 1995.
Approval Date:
Ultane was approved by FDA for market use on 07 June, 1995.
Active Ingredient:
Ultane uses Sevoflurane as the active ingredient. Check out other Drugs and Companies using Sevoflurane ingredient
Dosage:
Ultane is available in liquid form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100% | LIQUID | Prescription | INHALATION |